Literature DB >> 24050656

Multidrug-resistant Escherichia coli bacteremia.

Fahad Alhashash, Vivienne Weston, Mathew Diggle, Alan McNally.   

Abstract

Entities:  

Keywords:  E. coli; ESBL; Escherichia coli; ExPEC; MLST; antibiotic resistance; antimicrobial resistance; bacteremia; bacteria; multidrug resistance

Mesh:

Substances:

Year:  2013        PMID: 24050656      PMCID: PMC3810742          DOI: 10.3201/eid1910.130309

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Extraintestinal pathogenic Escherichai coli (ExPEC) bacteria have the ability to cause diverse and serious diseases, such as urinary tract infections (UTIs) and bacteremia (–); incidence of bacteremia is increasing globally (). The emergence of multidrug resistance in E. coli is also becoming a global concern, with particular emphasis on E. coli sequence type (ST) 131, which is being increasingly reported in UTIs. Drug resistance is mediated by extended-spectrum β-lactamases (ESBLs), mainly of the CTX-M family, particularly CTX-M-15 and 14, and less frequently of the SHV and OXA families (,). Few studies are available regarding the characterization of E. coli strains causing bacteremia. We characterized 140 E. coli isolates from bacteremia patients treated at Nottingham University Hospital (Nottingham, UK) over a 5-month period, with the aim of developing an epidemiologic profile of the population of ExPEC that causes bacteremia. For context, we compared the isolates with 125 E. coli isolates from urine samples collected during the same period. Cases were selected to include isolates from a diverse patient group: patient ages ranged from 1 month to 90 years; patient sex was evenly divided between male and female; infections were community- and hospital-associated; and suspected sources of infection varied. Antimicrobial drug susceptibility tests, PCR detection of ESBL genes, multilocus sequence typing using the Achtman scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli), and virulence-associated gene (VAG) carriage screening by PCR were performed on isolates as described (). Significantly more bacteremia E. coli isolates than urine E. coli isolates were resistant to ciprofloxacin (25.7% vs. 8.8%; p<0.001) and cefradine (20.0% vs. 11.2%; p<0.05). These results were reflected in the number of isolates in the 2 populations displaying a multidrug- resistance phenotype (resistance to antimicrobial drugs belonging to >2 classes); a significantly higher number of multidrug-resistant bacteremia E. coli isolates than multidrug-resistant urine isolates were found (50.7% vs. 32%; p = 0.01). PCR screening for ESBL carriage showed significantly higher ESBL carriage in bacteremia E. coli isolates than urine isolates for blaSHV (15.7% vs. 5.6%; p = 0.008), blaCTX-M (29.3% vs. 17.6%; p = 0.025), and blaOXA (14.3% vs. 6.4%; p = 0.037). Total ESBL carriage for bacteremia isolates was also significantly higher than for urine isolates (59.3% vs. 29.6%; p<0.001). Multilocus sequence types were determined for all E. coli isolates. A total of 63 STs were found among the urine isolates (Figure, panel A); the highest prevalence was ST73 (n = 16, 12.8%), followed by ST131 (n = 9, 7.2%), ST69 (n = 9, 7.2%), ST95 (n = 6, 4.8%), ST404 (n = 6, 4.8%), ST127 (n = 4, 3.2%), ST141 (n = 4, 3.2%), and ST10 (n = 3, 2.4%). Prevalence patterns of STs among bacteremia E. coli isolates were noticeably different (Figure, panel B). Three main STs were obtained. ST131 dominated (n = 30, 21.43%) and was significantly higher in prevalence than for the urine isolates (p<0.001). ST73 (n = 24, 17.14%) and ST95 (n = 13, 9.29%) were the other 2 primary STs found. The 8 most prevalent STs in the bacteremia isolates represented 59.29% of the total population, whereas the 8 most prevalent STs in the urine isolates represented 45.6% of the total population. This finding is suggestive of selection of a smaller number of dominant STs in bacteremia.
Figure

Minimum-spanning trees showing carriage of extended-spectrum β-lactamases (ESBL) in Escherichia coli isolates from urine samples (A) and samples from patients with bacteremia (B). Each circle represents 1 sequence type (ST), and the size of the circle reflects the number of isolates belonging to this particular ST within the bacteria group. Lines between the circles represent how different their allelic profiles are; a line labeled 1 means the linked STs differ in >1 of the 7 alleles, which is named a single locus variant (SLV). A cluster of STs linked by SLVs is a clonal complex. Nineteen (30.16%) of 63 STs found among the urine isolates were ESBL positive, in comparison to 30 (51.72%) of 58 for the bacteremia isolates.

Minimum-spanning trees showing carriage of extended-spectrum β-lactamases (ESBL) in Escherichia coli isolates from urine samples (A) and samples from patients with bacteremia (B). Each circle represents 1 sequence type (ST), and the size of the circle reflects the number of isolates belonging to this particular ST within the bacteria group. Lines between the circles represent how different their allelic profiles are; a line labeled 1 means the linked STs differ in >1 of the 7 alleles, which is named a single locus variant (SLV). A cluster of STs linked by SLVs is a clonal complex. Nineteen (30.16%) of 63 STs found among the urine isolates were ESBL positive, in comparison to 30 (51.72%) of 58 for the bacteremia isolates. ESBL carriage was mapped onto minimum-spanning trees for the 2 isolate groups. ESBL carriage among urine isolates was focused on a small number of STs; 19 (30.16%) of the 63 STs contained ESBL-positive isolates (Figure, panel A). The predominant ST73 group contained 18.75% ESBL-positive isolates; the other predominant STs exhibited ESBL-positive isolates at the following levels: ST131 (44.44%), ST69 (33.33%), ST95 (50%), and ST10 (0%). In contrast, 30 (51.72%) of the 58 STs among bacteremia isolates contained ESBL-positive isolates, significantly higher than for the urine isolates (p = 0.016). At the ST level, predominant STs had higher ESBL carriage in the bacteremia isolates than in the urine isolates: ST131 (50%), ST73 (50%), ST12 (75%), ST10 (100%), ST14 (50%), ST2278 (33.33%). ST95 (46.15%) and ST69 (20%) showed comparable levels. These results suggest that ESBL drug resistance is selecting for dominant ExPEC bacteremia strains. To investigate whether the differences in ST observations between bacteremia and urine isolates could be attributable to differences in virulence genes, VAGs of all isolates were screened by multiplex PCR. VAGs were found equally distributed across the 2 populations, with no statistically significant difference (p = 0.675). Comparison of serum resistance levels between urine and blood isolates also showed no phenotypic differences. In conclusion, we found high levels of ESBL carriage and multidrug resistance in ExPEC isolates that cause bacteremia. A comparison with urine isolates provided evidence that ESBL-mediated drug resistance appears to be the selective pressure in the emergence of dominant STs in bacteremia. Future research should focus on identifying if prolonged antimicrobial drug treatment in bacteremia patients is leading to this selection.
  7 in total

1.  Molecular epidemiology of extraintestinal pathogenic Escherichia coli isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings.

Authors:  Gemma Croxall; James Hale; Vivienne Weston; Georgina Manning; Phil Cheetham; Mark Achtman; Alan McNally
Journal:  J Antimicrob Chemother       Date:  2011-08-22       Impact factor: 5.790

Review 2.  Distribution and evolution of virulence factors in septicemic Escherichia coli.

Authors:  Eliora Z Ron
Journal:  Int J Med Microbiol       Date:  2010-05-26       Impact factor: 3.473

3.  The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System.

Authors:  M E A de Kraker; V Jarlier; J C M Monen; O E Heuer; N van de Sande; H Grundmann
Journal:  Clin Microbiol Infect       Date:  2012-10-08       Impact factor: 8.067

Review 4.  Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.

Authors:  Thomas A Russo; James R Johnson
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

5.  Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15.

Authors:  Marie-Hélène Nicolas-Chanoine; Jorge Blanco; Véronique Leflon-Guibout; Raphael Demarty; Maria Pilar Alonso; Maria Manuela Caniça; Yeon-Joon Park; Jean-Philippe Lavigne; Johann Pitout; James R Johnson
Journal:  J Antimicrob Chemother       Date:  2007-12-11       Impact factor: 5.790

Review 6.  Origins and virulence mechanisms of uropathogenic Escherichia coli.

Authors:  Travis J Wiles; Richard R Kulesus; Matthew A Mulvey
Journal:  Exp Mol Pathol       Date:  2008-04-08       Impact factor: 3.362

7.  UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone.

Authors:  Siu Ha Lau; Mary E Kaufmann; David M Livermore; Neil Woodford; Geraldine A Willshaw; Tom Cheasty; Katie Stamper; Suganya Reddy; John Cheesbrough; Frederick J Bolton; Andrew J Fox; Mathew Upton
Journal:  J Antimicrob Chemother       Date:  2008-09-08       Impact factor: 5.790

  7 in total
  24 in total

1.  Escherichia coli B2 Phylogenetic Subgroups in the Infant Gut Microbiota: Predominance of Uropathogenic Lineages in Swedish Infants and Enteropathogenic Lineages in Pakistani Infants.

Authors:  Forough L Nowrouzian; Olivier Clermont; Mona Edin; Anna Östblom; Erick Denamur; Agnes E Wold; Ingegerd Adlerberth
Journal:  Appl Environ Microbiol       Date:  2019-11-27       Impact factor: 4.792

2.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

Review 3.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 4.  The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.

Authors:  Amy J Mathers; Gisele Peirano; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Comparative Metabolic Characterization of Extraintestinal Pathogenic Escherichia coli Blood Isolates from Saudi Arabia.

Authors:  Abdulaziz Alangari; Ahmad Abu Jaffal; Abdulaziz M Alyousef; Abdullah A Alyousef
Journal:  J Trop Med       Date:  2022-05-30

6.  Antibiotic Multidrug Resistance of Escherichia coli Causing Device- and Procedure-related Infections in the United States Reported to the National Healthcare Safety Network, 2013-2017.

Authors:  Athena P Kourtis; Edward A Sheriff; Lindsey M Weiner-Lastinger; Kim Elmore; Leigh Ellyn Preston; Margaret Dudeck; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

7.  Bacteremia in Early Infancy: Etiology and Management.

Authors:  Joseph B Cantey; Amanda C Farris; Sarah M McCormick
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

8.  Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains.

Authors:  O Clermont; C Couffignal; J Blanco; F Mentré; B Picard; E Denamur
Journal:  Epidemiol Infect       Date:  2016-12-28       Impact factor: 4.434

9.  Comparative genome analysis identifies few traits unique to the Escherichia coli ST131 H30Rx clade and extensive mosaicism at the capsule locus.

Authors:  Abdulaziz Alqasim; Fleming Scheutz; Zhiyong Zong; Alan McNally
Journal:  BMC Genomics       Date:  2014-09-30       Impact factor: 3.969

10.  Phenotypic microarrays suggest Escherichia coli ST131 is not a metabolically distinct lineage of extra-intestinal pathogenic E. coli.

Authors:  Abdulaziz Alqasim; Richard Emes; Gemma Clark; Jane Newcombe; Roberto La Ragione; Alan McNally
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.